Qdenga Dengue Vaccine in India: What Parents in Kompally Should Know
On July 20, 2026, India's Central Drugs Standard Control Organisation (CDSCO) approved Qdenga, making it the country's first-ever approved dengue vaccine. For parents in Kompally and across Hyderabad — a city that sees a sharp rise in dengue cases every monsoon and post-monsoon season — this is genuinely significant news, and I've already been fielding questions about it in clinic. This guide covers what Qdenga is, who it's approved for, how well it works, and what it does (and doesn't) mean for your family this dengue season.
What Is Qdenga?
Qdenga — known scientifically as TAK-003 — is a live, attenuated (weakened) dengue vaccine developed by Takeda. It's built using a dengue serotype-2 virus as a "backbone," with genetic material from the other three dengue serotypes (DENV-1, DENV-3, and DENV-4) engineered into it. The goal of this design is to train the immune system to recognize and respond to all four dengue virus types with a single two-dose vaccine, rather than leaving a person protected against only one strain, which is often what happens after a single natural dengue infection.
Is Qdenga Approved in India?
Yes. CDSCO granted Qdenga marketing authorization on July 20, 2026, for individuals aged 4 to 60 years — and notably, the Indian approval allows its use regardless of whether someone has had dengue before. This is an important detail, because it's more permissive than the World Health Organization's current global guidance (more on that below).
It's worth being clear about what "approved" does and doesn't mean in practice: approval is a regulatory green light, not the same as nationwide availability. Qdenga is not yet part of India's public immunization program, and as of now it is expected to roll out in a phased manner through private healthcare settings.
Dosing Schedule
Qdenga is given as two doses, three months apart — one dose at month 0, and a second dose at month 3 — administered as a 0.5ml injection under the skin. The three-month gap shouldn't be shortened. If the second dose is delayed for any reason, the series doesn't need to be restarted; it can simply be completed at the next available opportunity, though sticking to the recommended schedule gives the most consistent protection.
How Effective Is Qdenga?
The evidence behind Qdenga comes from Takeda's Phase 3 TIDES trial, which followed roughly 20,000 children and adolescents across eight dengue-endemic countries in Asia and Latin America. Over 4.5 years of follow-up, the two-dose regimen showed 61.2% efficacy against virologically confirmed dengue of any severity, and — more importantly from a clinical standpoint — 84.1% efficacy against dengue hospitalizations, rising to 90.6% in those who received an additional booster dose. Follow-up data has shown protection persisting for up to seven years across all four dengue serotypes, though the degree of protection does vary somewhat by serotype and by a person's prior dengue exposure.
Why India's Approval Is Broader Than WHO's Current Guidance
This is a nuance worth understanding rather than glossing over. The World Health Organization's Strategic Advisory Group of Experts (SAGE) currently recommends Qdenga primarily for children aged 6–16 in settings with high dengue transmission intensity, and has stopped short of recommending its programmatic use in low-to-moderate transmission settings. The reason is that in the TIDES trial, children who had never been infected with dengue before (seronegative individuals) were only clearly protected against two of the four serotypes (DENV-1 and DENV-2), with less certainty around DENV-3 and DENV-4 protection in that group.
India's CDSCO approval, by contrast, permits use in ages 4–60 regardless of prior dengue exposure — reflecting a judgment that, in a high-burden country like India, the overall benefits outweigh the risks even with this remaining uncertainty. Both positions are evidence-based; they simply weigh the same data differently depending on a country's dengue burden. If your child hasn't had dengue before, it's a reasonable question to raise with your pediatrician when the vaccine becomes available, so you can make an informed decision together.
Safety and Side Effects
Qdenga has generally been well tolerated across its clinical trial program. The most commonly reported reactions in participants aged 4 to 60 were injection site pain (around 50%), headache (35%), muscle aches (31%), redness at the injection site (27%), and general malaise (24%) — nearly all mild and resolving within a few days. No serious safety concerns were identified, including after booster doses. As with any vaccine, individual suitability should be discussed with your pediatrician, particularly for children with underlying health conditions.
When Will It Be Available in Hyderabad, and What Will It Cost?
As of this writing, Qdenga has regulatory approval but hasn't yet launched commercially in India. Takeda has partnered with Biological E Limited, which is expected to support local manufacturing of up to 50 million doses annually — a step that should help both supply and, over time, affordability. Official pricing hasn't been announced, and rollout is expected to begin through private healthcare settings rather than government hospitals initially. We'll share updates as availability and pricing are confirmed for our clinic at KIMS Cuddles, Kompally.
Does This Mean You Can Stop Worrying About Mosquito Bites?
No — and this is worth emphasizing. No dengue vaccine, including Qdenga, offers complete protection against every serotype in every person. Vaccination should be thought of as an additional layer of protection on top of, not a replacement for, standard dengue prevention: eliminating stagnant water and mosquito breeding sites around the home, using mosquito repellents, and dressing children in protective clothing during peak mosquito activity hours (early morning and dusk) — especially important during Hyderabad's monsoon and post-monsoon dengue season, which typically runs from July through November.
Should You Get Qdenga for Your Child?
Hyderabad and the broader Telangana region see a real seasonal dengue burden, and a vaccine that meaningfully reduces the risk of hospitalization is a welcome addition to prevention. That said, the right decision for your child depends on their age, prior dengue history, and overall health — which is exactly the kind of individualized assessment worth doing with your pediatrician once the vaccine is available locally, rather than deciding from a news headline alone. If you'd like to discuss whether Qdenga is likely to be a good fit for your child once it launches, feel free to bring it up at your next visit.
Have questions about dengue prevention or vaccination for your child? Book a consultation with Dr. Suchit Jogu at KIMS Cuddles, Kompally.
Book an AppointmentRelated Pages
Frequently Asked Questions
What is Qdenga and how does the dengue vaccine work?
Qdenga (also known by its scientific name TAK-003) is a live, attenuated dengue vaccine made by Takeda. It's built on a weakened dengue serotype-2 virus "backbone," into which genes from the other three dengue serotypes (DENV-1, DENV-3, and DENV-4) have been inserted. This design allows a single two-dose vaccine to train the immune system to recognize all four dengue virus types, rather than protecting against just one strain the way natural infection often does.
Is the Qdenga dengue vaccine approved in India?
Yes. On July 20, 2026, India's Central Drugs Standard Control Organisation (CDSCO) granted marketing authorization to Qdenga, making it the first dengue vaccine approved for use in India. It's approved for individuals between 4 and 60 years of age, regardless of whether they've had dengue before. Approval doesn't mean nationwide availability yet — as of this writing, Qdenga is still working through phased introduction into private healthcare settings, and it is not yet part of India's public immunization program.
What is the Qdenga vaccine dosing schedule?
Qdenga is given as two doses, three months apart (at month 0 and month 3), as a 0.5ml injection under the skin. It's important not to shorten this three-month gap. If the second dose is delayed for any reason, there's no need to restart the whole series — it can simply be given at the next available opportunity, though completing both doses on schedule gives the most reliable protection.
How effective is Qdenga against dengue?
In Takeda's large Phase 3 TIDES trial, which followed around 20,000 participants across eight dengue-endemic countries, the two-dose regimen showed 61.2% efficacy against virologically confirmed dengue through 4.5 years of follow-up, and 84.1% efficacy against dengue hospitalizations (rising to 90.6% in participants who received a booster dose). Protection was shown to last up to seven years across all four dengue serotypes, though efficacy varies somewhat by serotype and by whether a person had prior dengue exposure.
What are the side effects of the Qdenga vaccine?
In clinical trials, Qdenga was generally well tolerated. The most commonly reported reactions were injection site pain (about 50% of recipients), headache (35%), muscle aches (31%), redness at the injection site (27%), and general malaise (24%) — all typically mild and short-lived. No serious safety concerns were identified in the trial data, including after a booster dose, though as with any vaccine, you should discuss your child's individual health history with your pediatrician before vaccination.
When will Qdenga be available in Hyderabad and how much will it cost?
As of August 2026, Qdenga has regulatory approval but has not yet launched commercially in India. Takeda has partnered with Biological E Limited, which is expected to support local manufacturing of up to 50 million doses a year, with availability planned in a phased rollout through private healthcare settings. Official pricing hasn't been announced yet. We'll share updates as availability and pricing details are confirmed for our clinic at KIMS Cuddles, Kompally.
Can children younger than 4 or adults older than 60 receive Qdenga?
India's current CDSCO approval covers ages 4 through 60. Safety and efficacy data for children younger than 4 and adults older than 60 hasn't been established in the same way, so the vaccine isn't currently indicated for those age groups. This may be revisited as more data becomes available — your pediatrician can advise on the most current guidance for your family.
Does getting the Qdenga vaccine mean we can stop worrying about mosquito bites?
No — vaccination should be seen as an additional layer of protection, not a replacement for standard dengue prevention. Since no dengue vaccine offers complete protection against every serotype in every person, continuing to eliminate mosquito breeding sites around the home, using repellents, and dressing children in protective clothing during peak mosquito activity (early morning and dusk) remains just as important, especially during Hyderabad's monsoon and post-monsoon dengue season.
Dr. Suchit Jogu is a Pediatrician and Pediatric Intensivist at KIMS Cuddles, Kompally, Hyderabad. For consultations, vaccination guidance, or pediatric emergencies, book an appointment today.
This article reflects publicly available information as of August 2026 and is for general educational purposes only — it isn't a substitute for personalized medical advice. Vaccine availability, pricing, and guidance may change; please confirm current details with your pediatrician before making a decision for your child.